Stock index futures were higher on Tuesday as tech stocks continued to recover, with the SpaceX IPO set for Friday. Here are ...

Pfizer (PFE) stock is in focus as mid-stage trial data support a once-monthly dosing regimen for GLP-1 therapy berobenatide.

Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 8:00 AM EDTCompany ParticipantsAlbert Bourla - Chairman of ...

Pfizer Inc. recently presented detailed Phase 2b results for berobenatide (PF’3944), an investigational once-weekly and ...

Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is back in focus after recent share price moves, with the stock ...

BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer on June 6 and set a price target of $34.00. Introducing TipRanks MCP for Agents. Deliver institutional-grade m ...

Pfizer (NYSE:PFE | PFE Price Prediction) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a ...

Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients.

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued US Stocks According to Hedge Funds. On May 13, Pfizer Inc.

Pfizer’s PFE stock declined a little more than 1% following its first-quarter 2026 results on May 5, despite beating ...

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per ...

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Pfizer Inc. (NYSE:PFE) is one of the most ...